Jayin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 4.49%
- Profit Growth 68.73%
- Ebitda 68.73%
- Net Worth -76.16%
- Total Assets -8.37%
About Jayin Pharmaceuticals
Jayin Pharmaceuticals Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 November 2019 (Five years and two months 24 days old ). Its registered office is in Tvs Showroom Muzaffarpur, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rachna Kumari and Amar Choudhary serve as directors at the Company.
Company Details
-
Location
Tvs Showroom Muzaffarpur, Bihar, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230BR2019PTC044242
-
Company No.
044242
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Nov 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Jayin Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rachna Kumari
|
Director | 25-Nov-2019 | Current |
|
Amar Choudhary
|
Director | 25-Nov-2019 | Current |
Financial Performance of Jayin Pharmaceuticals.
Jayin Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 4.49% increase. The company also saw a substantial improvement in profitability, with a 68.73% increase in profit. The company's net worth observed a substantial decline by a decrease of 76.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jayin Pharmaceuticals?
In 2022, Jayin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Lifekind Pharmaceuticals Private LimitedAmar Choudhary is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jayin Pharmaceuticals?
Unlock and access historical data on people associated with Jayin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jayin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jayin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.